* Heron Therapeutics Inc HRTX.OQ HRTX.O is expected
to show a
rise in quarterly revenue when it reports results on March 12
for the period ending December 31 2023
* The San Diego California-based company is expected to
report a
3.2% increase in revenue to $30.975 million from $30.03 million
a year ago, according to the mean estimate from 2 analysts,
based on LSEG data.The company's guidance on November 14 2023,
for the period ended December 31, was for revenue between $30.00
million and $32.00 million.
* LSEG's mean analyst estimate for Heron Therapeutics Inc
is for
a loss of 16 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Heron
Therapeutics Inc is $7.00, above its last closing price
of $2.59.
The company's guidance on November 14 2023 for the period ended
December 31 was for Earnings before Interest, Taxes,
Depreciation and Amortization of between 30 million and -6
million (USD).The company's guidance on November 14 2023 for the
period ended December 31 was for gross profit margin of USD62%.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Sep. 30 2023 -0.29 -0.29 -0.17 Beat 41.9
Jun. 30 2023 -0.23 -0.23 -0.35 Missed -50
Mar. 31 2023 -0.21 -0.20 -0.27 Missed -33
Dec. 31 2022 -0.30 -0.28 -0.17 Beat 40.4
Sep. -0.38 -0.38 -0.38 Met -1.1
30 2022
Jun. 30 2022 -0.53 -0.50 -0.55 Missed -8.9
Mar. 31 2022 -0.49 -0.48 -0.63 Missed -32.4
Dec. 31 2021 -0.58 -0.58 -0.54 Beat 6.3
This summary was machine generated March 8 at 21:48 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)